News

An under-the-skin injectable formulation of Remsima (infliximab), called Remsima SC, has been approved in European Union for the treatment of five autoimmune disorders, including ankylosing spondylitis. The approval by the European Commission also covers Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis,…

On days when they are more mindful or engaged in meaningful activities, people with ankylosing spondylitis or rheumatoid arthritis experience less impairment due to fatigue, a study suggests. The study, “Understanding fatigue‐related disability in rheumatoid arthritis and ankylosing spondylitis: The importance of daily correlates,” was…

The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), to treat chronic inflammatory disorders such as ankylosing spondylitis. However, Hulio (adalimumab-fkjp) — developed by Mylan and Fujifilm Kyowa Kirin Biologics — will not be available in the U.S. until July 31,…

The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), is recommending the use of a subcutaneous (under the skin) injection formulation of Remsima (infliximab) by people with ankylosing spondylitis and four other disorders. Celltrion Healthcare designed this new version…

The Alexion Charitable Foundation has awarded $1.1 million in grants to programs that support those with rare diseases during the COVID-19 pandemic, the organization recently announced. The grants will support activities that align with the foundation’s Rare Belonging focus, a set of funding priorities aimed at improving the…

Simponi (golimumab) — a TNF inhibitor — is an effective therapy for people with ankylosing spondylitis (AS) and other chronic inflammatory conditions, regardless of pre-treatment with other TNF inhibitors, real-world data from Germany suggested. While the best results were seen in patients given Simponi as a first-line treatment, these findings…

Cosentyx (secukinumab) has been approved in the U.S. to treat people with active non-radiographic axial spondyloarthritis (nr-axSpA), its developer, Novartis, has announced. The approval by the U.S. Food and Drug Administration (FDA) follows a similar decision by the European Commission in April. In both the…

Nepexto, a biosimilar to Enbrel (etanercept), has been approved by the European Commission to treat ankylosing spondylitis (AS) and several other inflammatory disorders. The therapy, co-developed by Mylan and Lupin, is expected to be available to patients in the European Union in the second…

The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in the rare disease community. Getting a timely and accurate diagnosis for a disease that few people — sometimes even physicians — have heard of is challenging on its own merit.